See Recent Shionogi-Sponsored Congress Presentations

Congresses

As part of our commitment to addressing unmet medical needs, Shionogi continues to investigate approved products and pipeline compounds. Shionogi presents its research at major congress events globally.

The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

Select a congress event or filter to view available congress presentations.

  • All
  • AAN
  • ESPID
  • APCCMI
  • ASCP
  • ASM Microbe
  • AVG and IMRP
  • CROI
  • ESCMID
  • GSA
  • IAS
  • IDWeek
  • ISIRV
  • NACFC
  • SCCM
  • All
  • 2024
  • 2025
  • 2026
  • All
  • Amyotrophic Lateral Sclerosis (ALS)
  • COVID-19
  • Gram-negative infection
  • Respiratory Syncytial Virus (RSV)
  • All
  • Cefiderocol
  • Edaravone
  • Ensitrelvir
  • S-337395
  • S-892216
  • Xeruborbactam
  • All
  • Oral presentation
  • Poster presentation

You Are Viewing Presentations

IDWeek 2024
Cefiderocol

Correlation analysis of cefiderocol in vitro activity and in vivo efficacy against Acinetobacter baumannii strains with difficult-to-read MIC endpoints

View/Download Presentation
GSA 2025
Ensitrelvir

COVID-19 exposure, treatment patterns, and healthcare utilization in US long-term care: retrospective EHR study

View/Download Presentation
ASCP 2025
Ensitrelvir

Current impact of COVID-19 in long-term care facilities in the United States: systematic literature review 

View/Download Presentation
IDWeek 2025
Cefiderocol

Earlier cefiderocol use was associated with better outcomes for challenging gram-negative bacterial infections: US results from the global observational PROVE study

View/Download Presentation
ESCMID 2026
Cefiderocol

Efficacy and safety of cefiderocol or colistin in a randomised, open-label phase 3 study in Chinese participants with carbapenem-resistant gram-negative bacterial infections

View/Download Presentation
IAS 2024
Ensitrelvir

Efficacy and safety of ensitrelvir in non-hospitalized adults at standard or high risk of progression to severe COVID-19: the SCORPIO-HR phase 3, randomized, double-blind, placebo-controlled trial

View/Download Presentation

You Are Viewing Congress Locations